Pas de connexion internet — affichage de la version enregistrée de la page.

Novartis AG ADR

USUSD
← Vers le screener

Novartis AG ADR (VI:NOVN) — Drug Manufacturers - General. Nombre de places boursières sur lesquelles les actions de la société sont cotées : 7. Sur cette page : cours et graphique, dividendes, principaux actionnaires et historique du nombre d'actions.

À propos de l'entreprise

Site web
novartis.com
Secteur
Healthcare · Drug Manufacturers - General
Siège social
BASEL, Switzerland
PDG
Vasant Narasimhan
Employés
75 267
Fondée
1996
Cotée depuis
07.05.2025 (VI:NOVN)
Actions en circulation
1.91 Md au 2025-12-31
Flottant
1.86 Md
Capitalisation boursière
276.48 Md USD
Initiés
0.01%
Investisseurs institutionnels
7.27%
Secteur d'activité (SIC)
Pharmaceutical Preparations
Forme juridique
MVII
ISIN
CH0012005267
LEI
5493007HIVTX6SY6XD66
Taux de distribution
56.0%
FCF
17.6 Md USD
44%
Dette
29.4 Md USD
1.0 ans de FCF
Ancienneté du dividende
20 ans
Bénéfices, FCF et dividendes versés — pour les 12 mois précédant 31.12.2025 (le dernier rapport de l'entreprise).
Description

Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.

Bourses et tickers

BourseTickerDevisePrixType
US USA StocksNVSEF OTCUSD139.9825 +3.12%actions ordinaires
LSE London Stock Exchange0QLR IOBCHF82.63 +0.00%actions ordinaires
MI Borsa Italiana (Milan)1NOVN secondaireEUR127.94 +1.33%actions ordinaires
SW SIX Swiss ExchangeNOVN principaleCHF119.8 -0.13%actions ordinaires
SW SIX Swiss ExchangeNOVNEE secondaireCHF120.02 -1.80%actions ordinaires
VI Vienna Stock ExchangeNOVN secondaireEUR127.32 -0.31%actions ordinaires
XETRA XetraNOT secondaireEUR126.82 +0.48%actions ordinaires

Cours sur 3 mois

jour de hausse jour de baisse date de détachement du dividende date de versementSurvolez / touchez un jour — cours d'ouverture, de clôture, plus haut et plus bas

Dividendes

12 derniers mois, US:NVSEF: 3.7 CHF (1 vers.)

Novartis AG ADR (NVSEF) verse des dividendes une fois par an. Au cours des 12 derniers mois, 3.7 CHF par action ont été versés (versements : 1). D'après l'historique des paiements, la prochaine date ex-dividende est prévue vers 11.03.2027. Historique des dividendes ininterrompu : 20 ans.

Date exVersementMontant%TypeTicker
2026-03-112026-03-123.7000 CHF3.2/3.2 %annuelUS:NVSEF
2025-03-122025-03-133.5000 CHF3.0/3.0 %annuelUS:NVSEF

Actualités de cette semaine

Pas encore d'actualités du site de l'entreprise.

publicité

Principaux actionnaires

DétenteurParticipationActionsDate du rapport
VANGUARD STAR FUNDS-Vang…1.35%27.43 M2026-07-31
VANGUARD TAX-MANAGED FUN…0.9%18.24 M2026-06-30
Fisher Asset Management,…0.76%15.52 M2026-06-30
iShares Trust-iShares Co…0.67%13.69 M2026-08-31
Goldman Sachs TRT II-Gol…0.6%12.19 M2026-07-31
Artisan Partners Funds I…0.51%10.29 M2026-06-30
Dodge & Cox Funds-Dodge…0.44%8.9 M2026-06-30
Morgan Stanley0.43%8.73 M2026-06-30
Dimensional Fund Advisor…0.4%8.12 M2026-06-30
Fidelity Concord Street…0.35%7.12 M2026-07-31
Primecap Management Comp…0.32%6.59 M2026-06-30
iShares Trust-iShares MS…0.32%6.53 M2026-08-31
LOOMIS SAYLES & CO L P0.26%5.24 M2026-06-30
MFS Series Trust XVII-MF…0.26%5.22 M2026-06-30
Bank of America Corporat…0.24%4.91 M2026-06-30
VANGUARD SPECIALIZED FUN…0.23%4.66 M2026-07-31
VANGUARD CHESTER FUNDS-V…0.21%4.25 M2026-06-30
Franklin Resources, Inc.0.16%3.25 M2026-06-30
Blackrock Inc.0.15%3.05 M2026-06-30
Goldman Sachs Group Inc0.15%2.98 M2026-06-30
Northern Trust Corporati…0.14%2.79 M2026-06-30
DFA INVESTMENT DIMENSION…0.11%2.14 M2026-04-30
LOOMIS SAYLES FUNDS II-L…0.07%1.42 M2026-06-30
VANGUARD HORIZON FUNDS-V…0.06%1.21 M2026-06-30
Franklin Mutual Series F…0.06%1.19 M2026-06-30
JANUS INVESTMENT FUND-Ja…0.05%949 7262026-06-30
Principal Funds, Inc-Equ…0.05%945 0912026-04-30
Dimensional ETF Trust-Di…0.04%888 8552026-04-30
Franklin Mutual Series F…0.04%812 6182026-06-30
Dimensional ETF Trust-Di…0.04%716 8362026-04-30
Pacer Advisors, Inc.0.02%482 1532026-06-30
Partners Capital Investm…0%24 3352026-06-30
Paradigm Asset Managemen…0%21 5142026-06-30
Generali Investments Cee…0%15 7292026-06-30